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Abstract
Treatment of people living with HIV (PLHIV) with latent tuberculosis (TB) infection using iso-
niazid preventive therapy (IPT) can reduce the risk of TB disease, however, the scale-up of
IPT among PLHIV in Thailand and worldwide has been slow. To hasten the implementation
of IPT in Thailand, we developed IPT implementation training curricula and tools for health
care providers and implemented IPT services in seven large government hospitals. Of the
659 PLHIV enrolled, 272 (41.3%) reported symptoms of TB and 39 (14.3% of those with TB
symptoms) were diagnosed with TB. A total of 346 (52.4%) participants were eligible for
IPT; 318 (91.9%) of these participants opted to have a tuberculin skin test (TST) and 52
(16.3% of those who had a TST) had a positive TST result. Among the 52 participants with a
positive TST, 46 (88.5%) initiated and 39 (75.0%) completed 9 months of IPT: physicians
instructed three participants to stop IPT, two participants were lost to follow-up, one chose
to stop therapy, and one developed TB. IPT can be implemented among PLHIV in Thailand
and could reduce the burden of TB in the country.
Introduction
Thailand, an upper-middle income country in Southeast Asia with a population of 68 million,
had an estimated tuberculosis (TB) incidence of 172 cases per 100,000 people in 2015 making
it one of 30 countries in the world classified by the World Health Organization (WHO) as hav-
ing the highest burden of TB [1]. Among people diagnosed with TB in Thailand in 2015, an
estimated 13% were also infected with HIV [1]. TB is the leading cause of death among people
living with HIV (PLHIV), and HIV infection increases the risk of rapidly progressing from TB
infection to TB disease [2]. Antiretroviral therapy (ART) reduces, but does not eliminate the
risk of TB disease among PLHIV [3–5]. Treatment of people with latent TB infection using
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isoniazid preventive therapy (IPT) can reduce the risk of latent TB infection progressing to TB
disease by 60% to 90% [6]. IPT offers protection from TB disease above and beyond the protec-
tion afforded by ART [7]. Therefore, the WHO recommends IPT for PLHIV as part of a TB
prevention package that includes infection control practices for TB and intensified case-find-
ing of TB (i.e., the Three I’s) [8–9].
Despite evidence that IPT reduces TB incidence in PLHIV and WHO recommendations
to incorporate IPT as part of comprehensive TB and HIV activities, scale-up of IPT among
PLHIV worldwide has been slow [10]. Implementation of IPT programs is challenging for
several reasons: careful coordination of activities is required among national and local TB
and HIV programs and clinics, PLHIV eligible for IPT are often identified in HIV clinics
and may need referral to TB clinics for clinical assessment and provision of IPT, and supply
chain management and follow-up care and monitoring issues can be complicated if they are
not standardized.
In Thailand, IPT is recommended for PLHIV who have latent TB infection based on a posi-
tive tuberculin skin test (TST) [11]. WHO recommendations do not require a TST to initiate
IPT among PLHIV [8]; however, because studies have shown significant reductions in incident
TB and mortality among PLHIV with positive TST results and not among PLHIV with nega-
tive TST results, the Thai government recommends TST [5,12]. In Thailand and many parts of
the world where TB is common, Bacillus Calmette-Guerin (BCG) vaccine is used to protect
infants and young children from serious life-threatening disease [13]. BCG vaccine can cause a
positive TST response, but this response generally wanes over time and, in Thailand, a TST
response showing induration of5 millimeters (mm) in PLHIV is defined as a positive TST
response [11–14].
In order to hasten the implementation of IPT among PLHIV nationwide, Thailand’s
Ministry of Public Health (MOPH) organized an IPT Guideline Committee with represen-
tatives from the MOPH Bureau of TB, the MOPH Chest Institute and Infectious Diseases
Hospital, the Thai Red Cross, University Hospitals, and the U.S. Centers for Disease Con-
trol and Prevention (CDC). The IPT Guideline Committee met in 2009 to review and align
existing IPT recommendations for PLHIV, develop IPT implementation training tools for
health care providers, and organize sustainable systems to deliver and store TST reagent
and isoniazid.
An IPT protocol was developed to guide implementation of IPT in selected hospitals in
Vietnam and Thailand. We identified seven large government hospitals with existing TB and
HIV services in Thailand to implement IPT services for PLHIV using the curricula and tools
developed by the Committee. Here, we report the results of the IPT program in Thailand two
years after implementation.
Methods
Development of curricula and tools
The IPT Guideline Committee reviewed existing national TB recommendations including the
2009 MOPH National HIV/TB Guidelines [15], the 2008 National Tuberculosis Control Pro-
gramme Guidelines [16], and the 2003 Implementation Manual for Treatment of PLHIV with
latent TB infection in Northern Thailand [17] to develop training tools. The draft IPT guide-
lines recommended 9 months IPT for PLHIV with latent TB infection and the staff training
tools included information on the evidence supporting the use of IPT among PLHIV, how to
screen PLHIV for TB disease and latent TB infection, how to record information gathered dur-
ing the screening process, how to monitor PLHIV receiving IPT, and hands-on training about
TST administration.
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The Thailand Vietnam IPT protocol recommended that participants with TB symptoms
who completed an evaluation for TB disease and were found not to have TB disease, be evalu-
ated for IPT; however, in Thailand, the IPT Guideline Committee recommended that only
people with a negative TB symptom screen be evaluated for IPT. Consistent with the guideline
committee recommendation, site staff at the seven hospitals in Thailand were instructed to
only evaluate participants with a negative TB symptom screen for IPT.
Study population
Seven hospitals were selected because they had well established HIV and TB treatment pro-
grams. In these hospitals, TB services (i.e., screening, diagnosis, and treatment) were provided
in the HIV clinic. The hospitals in Chiang Rai (756 beds), Nakhon Si Thammarat (1000 beds),
Phitsanulok (904 beds), and Phuket (534 beds) are urban, tertiary care, regional hospitals; Sri-
saket Hospital (506 beds) is an urban, tertiary care provincial hospital; Tak Hospital (310 beds)
is an urban, secondary care provincial hospital; and Chiang Mai Hospital (456 beds) is a rural,
secondary care district hospital. At the outpatient HIV clinics in these seven hospitals, staff
offered PLHIV18 years newly registered for HIV care or previously registered and being
evaluated for ART initiation an assessment for TB disease and latent TB infection.
Ethical considerations
Patients interested in participating in the study signed an informed consent form. The study
protocol was approved by the Ethical Review Committees of Nakhon Si Thammarat Hospital,
Phitsanulok Hospital, Chaing Rai Hospital, the Thailand MOPH, and the Institutional Review
Board of CDC and the study was conducted according to the principles expressed in the Decla-
ration of Helsinki.
Site preparation
In 2010, we trained approximately 25 staff (i.e., HIV and TB clinic staff, laboratorians, pharma-
cists, and social medicine staff) from the seven hospitals about latent TB, TB disease, and how
to implement IPT among PLHIV using the tools developed by the IPT Guideline Committee
(S1 File. Workshop on IPT and TST). Supply chains for TST reagents and isoniazid were
developed or strengthened at each hospital.
Participant evaluation
From July 2010 through August 2011, staff screened patients for TB disease using an evidence-
based TB symptom screening questionnaire [18]. The TB screening consisted of three ques-
tions: in the previous four weeks have you had 1) a cough or 2) a fever of any duration, or 3)
drenching night sweats lasting three or more weeks. Participants with newly diagnosed HIV
infection; or with fever, cough, or night sweats; or with clinical findings suggestive of TB were
referred for a chest x-ray. Participants with one or more TB symptoms or an abnormal chest
x-ray were sent for further evaluation including microbiologic examination of sputum and TB
treatment if diagnosed with TB disease. Participants with a negative TB symptom screen, a
normal chest x-ray (i.e., if a chest x-ray was done), and no history of TB disease or IPT use,
liver disease, or an opportunistic infection were offered a TST. Participants with5 mm of
induration at the site of the TST 48 to 72 hours after placement were offered isoniazid 300 mg
daily for 9 months. PLHIV receiving IPT were monitored at one month, and if there was no
evidence of isoniazid toxicity, adverse drug reactions, or TB disease, every three months
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thereafter. Liver enzymes were examined at baseline and six months. Participants were fol-
lowed for one year.
Data collection and analysis
Staff used an interviewer-administered questionnaire with participants to collect demographic
and risk behavior data, information about signs or symptoms of TB, liver disease, and oppor-
tunistic infection, and a history of TB or IPT at baseline and at one year. Staff abstracted labo-
ratory and clinical data from participants’ medical records. Health care providers completed a
questionnaire after the initial evaluation and usually within one month describing the findings
of the evaluation and classifying participants as having TB disease or not having TB disease.
We used this classification to define TB disease cases in the analysis. Approximately one year
after the initial evaluation, research staff contacted health care providers for information about
the people evaluated; several additional cases of TB disease were reported. We did not include
these cases in the analysis. We used the chi-square and Fisher’s exact tests to test for differences
in proportions. We used generalized estimating equations logistic regression to account for
possible site level clustering and to explore participant characteristics associated with TB dis-
ease and a positive TST result. We included all variables in multivariable analyses. We used
SPSS for Windows 18.0 (SPSS Inc. Chicago, Illinois, USA) and SAS version 9.3 (SAS Institute,
North Carolina, USA) for analysis.
Results
Participants
From July 2010 through August 2011, 659 PLHIV18 years not yet receiving ART enrolled in
the study (Fig 1). A total of 272 (41.3%) participants reported symptoms associated with TB
(i.e., in the previous four weeks had a cough or a fever of any duration, or drenching night
sweats lasting three or more weeks). Men (47.0%) were more likely to have TB symptoms than
women (35.6%) (p = 0.003), PLHIV who weighed <60 kilograms (46.0%) were more likely to
have TB symptoms than those who weighed60 kilograms (32.3%) (p = 0.0007), and PLHIV
with CD4 counts <200 cells/mm3 (62.0%) were more likely to have TB symptoms than those
who had CD4 counts200 cells/mm3 (32.8%) (p<0.0001) (Table 1).
Participants with TB symptoms
Among the 272 participants with TB symptoms, 39 (14.3%) were diagnosed with TB disease:
15 (38.5%) had Mycobacterium tuberculosis (MTB) identified in sputum cultures, 12 (30.8%)
had abnormal chest x-ray results without acid fast bacilli identified in sputum smears and were
diagnosed with TB, seven (17.9%) had abnormal chest x-ray results, acid fast bacilli identified
in sputum smears, and negative MTB cultures, three (7.7%) had MTB isolated from a lymph
node, one (2.6%) had MTB isolated from pleura, and one (2.6%) was diagnosed with TB men-
ingitis. In multivariable analysis, participants diagnosed with TB disease were more likely to
be35 years old (Odds Ratio (OR) 2.4, 95% confidence interval (CI) 1.0–5.7) and have a CD4
count<200 cells/mm3 (OR 2.5, 95% CI 1.4–4.4) and less likely to be female (OR 0.4, 95% CI
0.1–1.0) (Table 2).
One participant did not report fever, cough, or night sweats but was diagnosed with TB two
months after the TB screening assessment (described below). Assuming this participant was
infected with TB before the screening questions were asked, the sensitivity of the TB symptom
screening questionnaire was 97.5%, the specificity was 62.5%, the positive predictive value was
14.3%, and the negative predictive value was 97.2%. Participants who had cough and fever or
Isoniazid preventive therapy for latent TB
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Fig 1. Participant flow.
https://doi.org/10.1371/journal.pone.0184986.g001
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cough, fever and drenching night sweats accounted for 28 (71.8%) of participants diagnosed
with TB (Table 3).
Testing for latent TB infection
Among the 387 (58.7%) participants who did not have symptoms of TB disease, 42 (10.8%)
were not eligible for IPT. The most common reasons for being ineligible for IPT were previous
IPT (n = 21, 50.0%) and previous TB treatment (n = 9, 21.4%). A total of 345 (52.4%) partici-
pants were eligible for IPT and offered a TST and 318 (92.2%) of these participants opted to
have a TST done (Fig 1).
The median age of the 318 participants who had a TST placed was 36 years (interquartile
range 30–42 years) and 178 (56.0%) were women. Two (0.6%) participants did not return for













18–34 years 273 (41.4) 120 (44.0) 153 (56.0)
35 years 386 (58.6) 152 (39.4) 234 (60.6) 0.24
Median age, in years (interquartile range [IQR]) 36 (31–43) 36 (31–43) 36 (31–42)
Sex
Male 330 (50.1) 155 (47.0) 175 (53.0)
Female 329 (59.9) 117 (35.6) 212 (64.4) 0.003
Body weight (kg)
<60 433 (65.7) 199 (46.0) 234 (54.0)
60 226 (34.3) 73 (32.3) 153 (67.7) 0.0007
CD4 count (cells/mm3)
200 467 (70.9) 153 (32.8) 314 (67.2)
<200 192 (29.1) 119 (62.0) 73 (38.0) <0.0001
Median CD4 count, cells/mm3 (IQR) 312 (157–474) 231 (66–412) 358 (245–498)
Currently smokes cigarettes
No 504 (76.5) 200 (39.7) 304 (60.3)
Yes 155 (23.5) 72 (46.4) 83 (53.6) 0.13
Drinks alcohol‡
No 571 (86.6) 238 (41.7) 333 (58.3)
Yes 88 (13.4) 34 (38.6) 54 (61.4) 0.59
Province
Chiang Mai 119 (18.1) 71 (59.7) 48 (40.3)
Chiang Rai 229 (34.8) 70 (30.6) 159 (69.4)
Nakhon Si Thammarat 80 (12.1) 41 (51.2) 39 (48.8)
Phitsanulok 78 (11.8) 36 (46.2) 42 (53.8)
Phuket 73 (11.1) 14 (19.2) 59 (80.8)
Srisaket 36 (5.5) 36 (100.0) 0 (0.0)
Tak 44 (6.7) 4 (9.1) 40 (90.9) <0.0001
HIV, human immunodeficiency virus; TB, tuberculosis
*Had at least one of three TB symptoms in the previous four weeks: cough, fever, and/or drenching night sweats lasting for three or more weeks.
†Chi-square test assessing characteristics associated with TB symptoms.
‡Participant drinks alcohol every day or the participant consumes five or more alcohol containing drinks at one time at least once per week.
https://doi.org/10.1371/journal.pone.0184986.t001
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staff to read the TST result and 52 (16.4%) had a positive TST (5 mm of induration). None of
the 28 participants in Chiang Mai or the 39 participants in Phitsanulok had a positive TST;
while 15 (42.9%) of 35 in Nakhon Si Thammarat, 10 (25.0%) of 40 in Tak, 11 (20.4%) of 54 in
Phuket, and 16 (13.2%) of 121 participants in Chiang Rai, and had positive TST results. Partici-
pants with positive TST results did not differ significantly from those with negative TST results
by age, sex, weight, or CD4 count (Table 4).
Table 2. Results of generalized estimating equations logistic regression analysis of characteristics of people living with HIV with tuberculosis






Bivariable analysis Multivariable analysis
Odds Ratio (95% CI) P-value Odds Ratio (95% CI) P-value
Age
19–34 years (n = 120) 10 (8.3) 1.0 1.0
35 years (n = 152) 29 (19.1) 2.6 (1.1–5.9) 0.02 2.4 (1.0–5.7) 0.05
Sex
Male (n = 155) 30 (19.4) 1.0 1.0
Female (n = 117) 9 (7.7) 0.3 (0.2–0.8) 0.01 0.4 (0.1–1.0) 0.05
Body weight (kilograms)
<60 (n = 199) 32 (16.1) 1.0 1.0
60 (n = 73) 7 (9.6) 0.6 (0.3–1.2) 0.12 0.6 (0.3–1.2) 0.15
CD4 count (cells/mm3)
200 (n = 153) 13 (8.5) 1.0 1.0
<200 (n = 119) 26 (21.9) 3.0 (2.0–4.6) <0.0001 2.5 (1.4–4.4) 0.002
Currently smoke cigarettes
No (n = 200) 27 (13.5) 1.0 1.0
Yes (n = 72) 12 (16.7) 1.3 (0.6–2.5) 0.48 0.9 (0.4–2.5) 0.91
Drinks alcohol†
No (n = 238) 34 (14.3) 1.0 1.0
Yes (n = 34) 5 (14.7) 1.0 (0.7–1.6) 0.87 1.0 (0.7–1.3) 0.74
HIV, human immunodeficiency virus; TB, tuberculosis
*Had at least one of three TB symptoms in the previous four weeks: cough, fever, and/or drenching night sweats lasting for three or more weeks.
† Participant drinks alcohol every day or the participant consumes five or more alcohol containing drinks at one time at least once per week.
https://doi.org/10.1371/journal.pone.0184986.t002
Table 3. Assessment of 272 people living with HIV who reported tuberculosis symptoms at baseline.
TB symptom or symptoms Diagnosed with TB
N = 39
n (%)






Cough only 6 (8.0)* 69 (92.0)* 75 (27.6) †
Cough and fever 12 (16.4) 61 (83.6) 73 (26.8)
Cough, fever, and drenching night sweats 16 (25.4) 47 (74.6) 63 (23.2)
Fever only 2 (5.3) 36 (94.7) 38 (14.0)
Fever and drenching night sweats 1 (11.1) 8 (88.9) 9 (3.3)
Drenching night sweats only 0 (0) 5 (100) 5 (1.8)
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Isoniazid preventive therapy
Among the 52 participants with a positive TST, one decided not to start IPT, two had CD4
count results less than 200 cells/mm3 and their doctors decided to start ART first, and three
participants were lost to follow-up before being offered IPT (Fig 1). A total of 46 (88.5%) par-
ticipants initiated IPT and 39 (75.0%) completed nine months of IPT. Three (6.5%) partici-
pants were instructed to stop IPT by their physicians (two had elevated aminotransferase
results and one had a skin rash), two (4.3%) were lost to follow-up, one (2.2%) stopped taking
IPT on their own, and one (2.2%) developed TB disease. The participant who developed TB
disease had a normal chest x-ray, a CD4 count of 333 cells/mm3, and a TST of 20 mm at base-
line. The participant returned to the clinic after 2 months of IPT with a fever, had an abnormal
chest x-ray and a negative sputum smear for TB, but was empirically diagnosed and started on
treatment for TB disease. The participant completed TB treatment without complications and
was alive and well at the one year follow-up visit.
Adverse drug reactions
One participant developed a skin rash that was not described in detail in the medical record.
The participant’s physician stopped all medicines including isoniazid and ART, the rash sub-
sided, and ART was restarted. Two participants had elevated alanine aminotransferase results
and their physicians stopped isoniazid. Both participants were alive and well, and had not
restarted IPT at the one year follow-up visit.
Table 4. Results of generalized estimating equations logistic regression analysis of baseline characteristics of 316 people living with HIV who had
a tuberculin skin test (TST) to determine predictors of a positive TST result (5mm of induration).










19–34 years (n = 131) 25 (19.1) 1.0 1.0
>34 years (n = 185) 27 (14.6) 0.7 (0.4–1.2) 0.22 0.8 (0.5–1.2) 0.28
Sex
Male (n = 139) 25 (18.0) 1.0 1.0
Female (n = 177) 27 (15.3) 0.8 (0.7–1.0) 0.07 0.7 (0.3–1.3) 0.25
Weight (kg)
<60 (n = 188) 32 (17.0) 1.0 1.0
60 (n = 128) 20 (15.6) 0.9 (0.6–1.3) 0.56 0.8 (0.5–1.3) 0.46
CD4 count (cells/mm3)
200 (n = 264) 44 (16.7) 1.0 1.0
<200 (n = 52) 8 (15.4) 0.9 (0.4–2.3) 0.84 0.9 (0.4–2.2) 0.82
Currently smokes cigarettes
No (n = 248) 42 (16.9) 1.0 1.0
Yes (n = 68) 10 (14.7) 0.8 (0.3–2.2) 0.73 0.8 (0.3–2.3) 0.67
Drinks alcohol*
No (n = 274) 48 (17.5) 1.0 1.0
Yes (n = 42) 4 (9.5) 0.5 (0.1–2.5) 0.39 0.5 (0.1–2.4) 0.37
CI, confidence interval; kg, kilograms.
*Participant drinks alcohol every day or the participant consumes five or more alcohol containing drinks at one time at least once per week.
https://doi.org/10.1371/journal.pone.0184986.t004
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Discussion
Hospital staff assessed 659 PLHIV and found that 52.4% were eligible for a TST; 16.4% of the
318 who chose to have a TST tested positive for latent TB infection. Of those diagnosed with
latent TB infection 75.0% completed 9 months of IPT. These findings demonstrate that with
appropriate preparation, training, and support hospital staff in Thailand can successfully
implement IPT among PLHIV. Among PLHIV who reported TB symptoms in the screening
assessment (i.e., in the previous four weeks had a cough or a fever of any duration, or drench-
ing night sweats lasting three or more weeks) 14.3% were diagnosed with TB disease. The sen-
sitivity, specificity, and predictive values of the three questions TB screening algorithm among
participants in this study were similar to results reported in the literature [18].
In 2014, only 13 of 41 high TB/HIV burden countries reported to WHO that IPT had been
provided to PLHIV to prevent TB disease. Among the 13 countries reporting to WHO, IPT
coverage ranged from 5% in Swaziland to 97% in Haiti [1]. Several studies have assessed IPT
among PLHIV at sites in Thailand. In a study in northern Thailand in the mid-1990s among
412 PLHIV with positive TST results, 286 (69.4%) completed 9 months of IPT; female partici-
pants and participants who were married, widowed, or self-employed were more likely to be
adherent to IPT [14]. A similar study at an AIDS research center in Bangkok during 2003–
2008 among 799 participants with positive TST results, found that 551 (69.0%) completed 9
months of IPT and participants with baseline CD4 counts >200 cells/mm3 were more likely to
complete 9 months of IPT [19]. Consistent with these studies, we found high uptake (88.5%)
and completion (75.0%) of IPT among PLHIV and use of TST reduced the number of PLHIV
targeted for IPT from 346 (52.4%) to 52 (7.9%). Despite evidence that IPT can reduce the bur-
den of TB and WHO recommendations to provide IPT to PLHIV, health care worker concerns
about excluding TB disease, creating isoniazid resistance, hepatitis, and IPT adherence have
limited the scale-up IPT nationally in Thailand [20].
There were an estimated 455,000 PLHIV in Thailand in 2014 [21]. Based on our findings
(i.e., 318 [48.3%] of the 659 PLHIV evaluated were eligible for and opted to have a TST placed
and 52 [16.3%] of these participants had a positive TST result), approximately 36,000 PLHIV
would have a positive TST result and be eligible for IPT. A study in New York City in 1985–
1987 found that PLHIV with positive TST results developed TB disease at a rate of 7.9 per 100
person-years [2], suggesting that 2,800 cases of TB could potentially be prevented in Thailand
each year if IPT were made available to PLHIV. Thailand is one of 30 countries in the world
with the highest burden of TB and TB causes substantial morbidity and mortality in the coun-
try, particularly among PLHIV. Assessing PLHIV for TB disease and providing IPT to those
who are eligible would reduce the incidence of TB among PLHIV, prevent new infections, and
thereby reduce the burden of TB in Thailand.
Our report has several limitations. We implemented the IPT activity in hospitals that had
well developed HIV and TB services; other facilities may not be able to provide the same level of
care. In settings where TST is not available, IPT should be considered for all PLHIV as recom-
mended by WHO [8]. We did not use new molecular diagnostic laboratory technologies. These
automated diagnostic tools can decrease the time to diagnosis of TB and drug resistant TB, have
improved sensitivity for diagnosing disease, and may provide healthcare workers with greater
confidence that they have excluded TB disease and can safely initiate IPT among PLHIV [22].
Participants who did not report fever, cough, or night sweats and did not have clinical findings
or chest x-ray results suggestive of TB were not systematically evaluated for TB with sputum
microbiologic exam. Thus, some cases of TB disease may have been missed in this population.
Based on the recommendations of the National IPT Guideline Committee and the success-
ful implementation of IPT in seven hospitals, the Thailand MOPH recommended that all
Isoniazid preventive therapy for latent TB
PLOS ONE | https://doi.org/10.1371/journal.pone.0184986 September 26, 2017 9 / 12
PLHIV be assessed for and offered IPT for latent TB infection in the 2013 National Tuberculo-
sis Control Guidelines [11] and included the treatment recommendations for PLHIV with
latent TB infection in the Thailand National Guidelines on HIV/AIDS issued in 2017 [23]. The
capacity of hospital staff to implement TB screening and IPT will need to be increased to make




S1 File. Workshop on IPT and TST. S1 File contains a workshop agenda, sample of overview
ICF-IPT project in Thailand, sample of IPT study, and sample of latent TB infection and TST.
(PDF) Figure A. Workshop agenda. (PDF) Figure B. Sample of overview ICF-IPT project in
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